Ticker

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) — Algern

Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) — Algerno

A Pill That May Lessen COVID-Related Lung Damage. Miami Will Be First In U.S. To Test It

A Miami hospital will be the first in the country to test…

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment

VANCOUVER, British Columbia, July 21, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19

VANCOUVER, British Columbia, June 25, 2020 (GLOBE NEWSWIRE) — Algerno

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

VANCOUVER, British Columbia, June 04, 2020 (GLOBE NEWSWIRE) — Algerno